Remove Bioassay Remove Genome Remove Production
article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

Some of the variables include the chemical composition of the LNP, the manufacturing process and of course the RNA itself, whose design and production must elicit the intended therapeutic outcome.” They can’t be derived from animal products, but they are often synthesised in low purity – 60%-70% pure. weight abundance.

Bioassay 130
article thumbnail

4th Gene Therapy Analytical Development Summit 2022

pharmaphorum

This year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech, pharma and academia to continue to develop resilient, long-lasting and robust analytical tools to enhance the safety, quality, and efficacy of gene therapy products.